EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer

Tatjana Geukens, Maxim De Schepper, François Richard, Marion Maetens, Karen Van Baelen, Amena Mahdami, Ha-Linh Nguyen, Edoardo Isnaldi, Sophia Leduc, Anirudh Pabba, Gitte Zels, Freya Mertens und 9 weitere

European Journal of Cancer · 2023-07 · 188 · 152-160

DOI: 10.1016/j.ejca.2023.04.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023-07. Verfasst von Tatjana Geukens und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, Univ…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Anti-HER2 antibody-drug conjugates (ADCs) have shown important efficacy in HER2-low metastatic breast cancer (mBC). Criteria for receiving ADCs are based on a single assay on the primary tumour or a small metastatic biopsy. We assessed the intra-patient inter-metastasis heterogeneity of HER2-low status in HER2-negative mBC. PATIENTS AND METHODS: We included samples of 10 patients (7 ER-positive and 3 ER-negative) donated in the context of our post-mortem tissue donation program UPTIDER. Excisional post-mortem biopsies of 257 metastases and 8 breast tumours underwent central HER2 immunohistochemistry (IHC), alongside 41 pre-mortem primary or metastatic samples. They were classified as HER2-zero, HER2-low (HER2-1+ or HER2-2+, in situ hybridisation [ISH] negative) or HER2-positive (HER2-3+ or HER2-2+, ISH-positive) following ASCO/CAP guidelines 2018. HER2-zero was further subdivided into HER2-undetected (no staining) and HER2-ultralow (faint staining in ≤10% of tumour cells). RESULTS: Median post-mortem interval was 2.5 h. In 8/10 patients, HER2-low and HER2-zero metastases co-existed, with the proportion of HER2-low lesions ranging from 5% to 89%. A total of 32% of metastases currently classified as HER2-zero were HER2-ultralow. Intra-organ inter-metastasis heterogeneity of HER2-scores was observed in the liver in 3/6 patients. Patients with primary ER-positive disease had a higher proportion of HER2-low metastases as compared to ER-negative disease (46% versus 8%, respectively). At the metastasis level, higher percentages of ER-expressing cells were observed in HER2-low or -ultralow as compared to HER2-undetected metastases. CONCLUSIONS: Important intra-patient inter-metastasis heterogeneity of HER2-low status exists. This questions the validity of HER2-low in its current form as a theranostic marker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorIn Situ HybridizationBiopsy

Stichwörter der Autor:innen

Antibody-drug conjugateBreast cancerHER2-lowHeterogeneityMetastasis

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
  • Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.
  • Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.

Zitieren

APA

Geukens, T., De Schepper, M., Richard, F., Maetens, M., Van Baelen, K., Mahdami, A., Nguyen, H. L., Isnaldi, E., Leduc, S., Pabba, A., Zels, G., Mertens, F., Vander Borght, S., Smeets, A., Nevelsteen, I., Punie, K., Neven, P., Wildiers, H., Van Den Bogaert, W., …, & Desmedt, C. (2023). Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. European Journal of Cancer, 188, 152-160. https://doi.org/10.1016/j.ejca.2023.04.026

Vancouver

Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Mahdami A, et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. European Journal of Cancer. 2023;188:152-160. doi:10.1016/j.ejca.2023.04.026

BibTeX
@article{Geukens2023,
  author = {Geukens, Tatjana and De Schepper, Maxim and Richard, François and Maetens, Marion and Van Baelen, Karen and Mahdami, Amena and Nguyen, Ha-Linh and Isnaldi, Edoardo and Leduc, Sophia and Pabba, Anirudh and Zels, Gitte and Mertens, Freya and Vander Borght, Sara and Smeets, Ann and Nevelsteen, Ines and Punie, Kevin and Neven, Patrick and Wildiers, Hans and Van Den Bogaert, Wouter and Floris, Giuseppe and Desmedt, Christine},
  title = {Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer},
  journal = {European Journal of Cancer},
  year = {2023},
  volume = {188},
  pages = {152--160},
  doi = {10.1016/j.ejca.2023.04.026}
}
Kostenlos starten →